Overview

Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State

Status:
Completed

Trial end date:
2010-01-01

Target enrollment:

Participant gender:

Summary

To assess the relative bioavailability of dapagliflozin and metformin from the two FDC formulations, comprised of 10 mg dapagliflozin and 1000 mg metformin XR, relative to coadministration of a dapagliflozin 10 mg tablet and 2 x 500 mg Glucophage® XR tablets, in healthy subjects in a fasted state.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Bristol-Myers Squibb

Treatments:

Dapagliflozin
Metformin